QBiotics CFO and Company Secretary update

BRISBANE, 22 January 2026

QBiotics Group Limited (QBiotics) announces that Brendan Brown has been appointed Chief Financial Officer, and Elissa Hansen has been appointed Company Secretary, succeeding Michael Wenzel who has resigned as Chief Financial Officer (CFO) and Company Secretary, with effect from 23 January 2026.

Brendan Brown is a Partner and Director at Prime Accounting & Business Advisory Pty Ltd, part of the Prime Financial Group. He is a Chartered Accountant (CA ANZ) and Registered Tax Agent and holds a Bachelor of Business (Accounting) from La Trobe University. With a strong background in accounting and business advisory - particularly in the life sciences sector - Brendan brings deep expertise to QBiotics’ financial strategy and operations. He is also a recognised expert in the Research & Development Tax Incentive and other government funding programs. Brendan will be joining QBiotics on a part-time contracted basis.

Elissa Hansen has more than 20 years’ experience advising boards and management on corporate governance, compliance, investor relations and other corporate related issues. She has worked with boards and management across a range of ASX listed companies, including assisting companies through the IPO process. Elissa is a Chartered Secretary who brings best practice governance advice, Corporations Act and other relevant legislation. Elissa is a Fellow of the Governance Institute of Australia and Graduate Member of the Australian Institute of Company Directors. She has a Bachelor of Commerce and a Graduate Diploma in Applied Corporate Governance.

Interim Chief Executive Officer and Managing Director, Ebru Davidson commented, “On behalf of the Board, I thank Michael for his valuable contribution as CFO and Company Secretary across the last 9 years. Through his tenure, Michael has played an important role across the areas of finance, governance, compliance and operations. We wish him well in his future endeavours.

I am also pleased to welcome Brendan Brown as Chief Financial Officer and Elissa Hansen as Company Secretary. We look forward to the expertise, advice and experience they will each bring to their roles with QBiotics.”

—ends—
 

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS

QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need. 

Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.

QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.

A veterinary formulation of tigilanol tiglate (STELFONTA^®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA^®.

Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.